HISAMITSU REPORT--PHASE 2-PRODUCT MIX ANALYSIS.pptVIP免费

PhaseIIReport:ProductMixAnalysisforHisamitsuChinaMarketEntryProjectApril6,2004April30,2025Confidential,Copyright@2003bySinotrust2HisamitsuChinaMarketEntryStrategyContentsAnalysisofHisamitsu’sproductsectorMarketrecaptureofHisamitsu’sproductsSummaryofintervieweeopinionsBriefintroductionofcompetitiveproductsHisamitsu’sproductpositioningHisamitsu’sdrugs(S1-S5,M)Byebye-feverLifecellaSuggestionsonmarketentryforHisamitsu’sproductsApril30,2025Confidential,Copyright@2003bySinotrust3HisamitsuChinaMarketEntryStrategyAnalysisofHisamitsu’sproductsApril30,2025Confidential,Copyright@2003bySinotrust4HisamitsuChinaMarketEntryStrategyHisamitsu’sproductmixWidthofProductMixLengthofProductMixOTCProductRXProductCosmeticDailyNecessitiesandMiscellaneousGoodsSALONPASMOHRUSTAPELIFECELLAByeBye-FEVER•Salonpas•MohrusTape•FaceMask•Byebye-fever•SalonpasHot•OrangeMask•SalonpasHot(glycolsalicylate)•CoolMask•SalonpasGel-patch•WhiteningMask•SalonpasHotSoothingGel-patch•ClayBaseGelMask•EssenceSheetMaskCeramideApril30,2025Confidential,Copyright@2003bySinotrust5HisamitsuChinaMarketEntryStrategyAbbreviatedcodesofHisamitsu’sproductswouldbeusedinthereportinordertoprovideaclearandbriefstatementSalonpasSalonpasHotSalonpasGel-patchSalonpasHotSoothingGel-patchMohrusTapeByeBye-FEVERS1S2S4S5MBBFSalonpasHot(glycolsalicylate)S3Hisamitsu’sproductsCodeApril30,2025Confidential,Copyright@2003bySinotrust6HisamitsuChinaMarketEntryStrategySummaryofintervieweeopinionsMarketrecaptureofHisamitsu’sproductsectorBriefintroductionofcompetitiveproductsApril30,2025Confidential,Copyright@2003bySinotrust7HisamitsuChinaMarketEntryStrategyTotalChinamarketsizeofproductssimilartoHisamitsu’sproductsisaboutUS$400millionNote:SourcefromPhaseIReportHisamitsu’sproductsSALONPASLIFECELLAMOHRUSTAPEByeBye-FEVERMarketSize(MNUS$)GrowthRate(%)270(painrelievingplaster)120(facemask)20%(especiallysomeethicalpainrelievingplasterswithahigherspeed)20%(clothmaskwithahigherspeed)ThemarketsizeislessthanUS$10million.April30,2025Confidential,Copyright@2003bySinotrust8HisamitsuChinaMarketEntryStrategyMarketsegmentationofpainrelievingplasters:TotalsalesisaboutUS$270million(recaptureofphaseIreport)00.10.20.30.40.50.60.70.80.911.11.21.31.41.51.61.71.81.92US$/patchPriceSegmentTraditionalChinesepainrelievingplasterEthicalmedicine1.85-1.88•ThetypicalmanufacturerisCheezhengTibetanmedicinegroupcorporation.•Thetypicalbrandis“CheezhengPainRelievingPlaster”.•ItsellswellbecauseofitslistedintoNationalReimbursementMedicineCatalog,successfulsalespromotionanddistinctcurativeeffect.•ThetwotypicalmanufacturersareHenanLingruipharmaceuticalco.,ltd.(typicalbrands:“Strengthen-boneMuskPainRelievingPlaster”&“CollateralChannelsInvigoratingandPainExpellingPlaster”)andGuilinTianhepharmaceuticalco.,ltd.(typicalbrand:“MuskStrengthen-bonePlaster”)0.50.1Note:SourcefromPhaseIReportApril30,2025Confidential,Copyright@2003bySinotrust9HisamitsuChinaMarketEntryStrategyMarketsegmentationofantipyreticmedicaldevices(recaptureofphaseIreport)Price(US$/patch）MarketingShare15432Yitieliang(Teiyaku)InstantIcePackYitieliang(Hakugen)Cold/HotPackChiefBrandsChiefBrandsCommonPriceUS$0.5-1/patchCommonPriceUS$0.5-1/patchNote:SourcefromPhaseIReportApril30,2025Confidential,Copyright@2003bySinotrust10HisamitsuChinaMarketEntryStrategyMarketsegmentationofclothfacemasks:To...